Phibro Animal Health Corp (NASDAQ:PAHC) VP Daniel M. Bendheim sold 2,500 shares of the stock in a transaction on Wednesday, September 12th. The stock was sold at an average price of $44.30, for a total value of $110,750.00. Following the completion of the sale, the vice president now owns 2,500 shares in the company, valued at approximately $110,750. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
NASDAQ PAHC traded down $0.48 during trading hours on Monday, reaching $42.91. 55,700 shares of the stock traded hands, compared to its average volume of 112,094. Phibro Animal Health Corp has a 1 year low of $32.05 and a 1 year high of $54.62. The company has a quick ratio of 1.66, a current ratio of 2.90 and a debt-to-equity ratio of 1.62. The company has a market capitalization of $1.73 billion, a price-to-earnings ratio of 25.02, a PEG ratio of 2.48 and a beta of 0.91.
Phibro Animal Health (NASDAQ:PAHC) last released its quarterly earnings results on Monday, August 27th. The company reported $0.46 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.42 by $0.04. Phibro Animal Health had a return on equity of 39.81% and a net margin of 7.90%. The business had revenue of $211.80 million for the quarter, compared to the consensus estimate of $209.27 million. During the same quarter last year, the business posted $0.39 earnings per share. The company’s revenue for the quarter was up 8.7% on a year-over-year basis. On average, equities analysts expect that Phibro Animal Health Corp will post 1.8 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which was paid on Wednesday, September 26th. Shareholders of record on Wednesday, September 5th were given a dividend of $0.10 per share. The ex-dividend date was Tuesday, September 4th. This represents a $0.40 dividend on an annualized basis and a yield of 0.93%. Phibro Animal Health’s payout ratio is 22.99%.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in PAHC. Ceredex Value Advisors LLC purchased a new stake in Phibro Animal Health during the first quarter valued at about $45,153,000. Segall Bryant & Hamill LLC purchased a new stake in Phibro Animal Health during the second quarter valued at about $21,724,000. BlackRock Inc. raised its position in Phibro Animal Health by 12.1% during the first quarter. BlackRock Inc. now owns 3,068,509 shares of the company’s stock valued at $121,821,000 after purchasing an additional 330,614 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Phibro Animal Health by 18.2% during the second quarter. Renaissance Technologies LLC now owns 634,500 shares of the company’s stock valued at $29,219,000 after buying an additional 97,700 shares during the last quarter. Finally, Granite Investment Partners LLC grew its stake in shares of Phibro Animal Health by 43.8% during the second quarter. Granite Investment Partners LLC now owns 312,978 shares of the company’s stock valued at $14,413,000 after buying an additional 95,308 shares during the last quarter. Institutional investors and hedge funds own 49.19% of the company’s stock.
A number of equities research analysts recently issued reports on the company. BidaskClub upgraded Phibro Animal Health from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th. Morgan Stanley increased their price objective on Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a research report on Wednesday, August 29th. Zacks Investment Research downgraded Phibro Animal Health from a “hold” rating to a “sell” rating in a research report on Wednesday, August 29th. Finally, Barclays increased their price objective on Phibro Animal Health from $31.00 to $33.00 and gave the stock an “underweight” rating in a research report on Thursday, July 5th. Three analysts have rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $43.20.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Further Reading: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.